To mark upcoming Rare Disease Day, pharmaphorum asked a panel of experts to give their thoughts on the opportunities and challenges facing developers of rare disease therapies in 2024.
Gilead Sciences has beefed up its pipeline with an agreement to buy CymaBay Therapeutics and its seladelpar drug for rare liver disease primary biliary cholangitis (PBC),
2024 has started on a low for US biotech Anavex Life Sciences, which saw its shares fall sharply this morning after Rett syndrome candidate Anavex 2-73 failed a clinical trial.
Leela Barham uses the very latest data – running up to November 2023 – to take stock of NICE’s Single Technology Appraisal (STA) recommendations on orphan drugs versus non-orphans.